Study at a glance
How was vitamin D tested in nerve cells, brain immune cells and worms?
Researchers used rodent nerve cells grown in the laboratory, microglia and worms to investigate vitamin D-related responses to injury. Microglia are immune cells in the brain. Cell experiments tested active vitamin D and changes in the amount of vitamin D receptor, the protein that receives vitamin D signals. They did not test supplements in people with diseases of the brain or nerves.
Did active vitamin D reduce signs of cell injury?
Active vitamin D or extra receptor reduced selected signs of chemical stress and partly preserved a measurement related to the cell’s energy-producing structures. Some signals of inflammation and damage to cell membranes also fell in microglia. Reducing receptor production generally worsened injury-related responses. These tests did not directly measure whole-brain energy production, long-term nerve-cell survival or a reduction in every inflammatory process.
Could the enzyme DUB3 help explain the cell responses?
An enzyme called DUB3 increased the amount of receptor protein without a matching increase in the RNA instructions for making it. Other experiments suggested that DUB3 helped the receptor last longer. Changing DUB3 also changed some injury responses. However, the study did not prove that every protective effect required the vitamin D receptor; other proteins could be involved.
Do these findings show a treatment for Parkinson’s disease?
Worm experiments are not human brain experiments. One protein signal was measured in worm muscle, and the worms received vitamin D3 rather than the active hormone used in the cells grown in the laboratory. Some method descriptions were inconsistent, and the cell experiments were repeated independently only a few times. The findings support further research, but do not establish Parkinson’s disease prevention or treatment, improved thinking ability, or a safe and effective supplement dose.
Read the full article below ↓Experiments in cultured rodent cells and worms suggest that vitamin D receptor signalling can influence selected neuronal injury and microglial inflammatory responses. A 2024 study also linked an enzyme called DUB3 to receptor stability. These findings support further mechanistic research, but do not establish protection against neurological disease in people. For the detailed methods and appraisal, read Vitamin D, Microglia and Oxidative Neuroprotection: Full Study.
What was tested
Zheng and colleagues studied neurons, microglia and several worm strains. Microglia are immune cells within the brain. Neuronal cultures were challenged with rotenone, a mitochondrial toxin; microglial cultures received fluid from cells engineered to produce more alpha-synuclein. The researchers applied calcitriol, the active vitamin D hormone, and separately increased or reduced vitamin D receptor expression.
What changed in the cells
Calcitriol or increased receptor expression reduced an oxidant-sensitive fluorescence signal and partly preserved a mitochondrial membrane-potential measurement. These are relevant to oxidative stress, but do not directly measure whole-brain energy production or long-term neuronal survival. Reducing receptor expression generally worsened the injury-related responses.
In microglia, the interventions reduced selected inflammasome-related signals, caspase-1 activity and measures of membrane injury. An inflammasome is a protein complex involved in inflammatory signalling. The measurements support a bounded cellular effect; they do not demonstrate that every inflammatory process was suppressed or that one specific cell-death mechanism explains all the findings.
Why receptor stability matters
Increasing DUB3 raised receptor protein abundance without a significant corresponding rise in receptor messenger RNA. Protein-turnover and association experiments supported a role in stabilising the receptor. DUB3 manipulation also changed injury responses, but the study did not establish that every protective DUB3 effect required the receptor. Other molecular targets remain possible.
Limits of the evidence
The worm experiments add biological observations but cannot be treated as human brain experiments. The alpha-synuclein reporter in one strain was expressed in muscle. Worm vitamin D3 exposure also differed from the calcitriol used in mammalian cultures, and a related worm receptor does not establish an identical human signalling mechanism.
Several methods descriptions are inconsistent, including the species named for primary neuronal cultures and the timing of worm gene suppression. Cell experiments used small replicate numbers, and the statistical report incompletely identifies its multiple-comparison procedure. These issues limit confidence in exact reconstruction and broad generalisation.
The complete article and supplementary material support a model-specific hypothesis connecting receptor signalling, protein stability and cellular stress. They do not establish prevention or treatment of Parkinson’s disease, a safe or effective supplement dose, or improved cognition. Clinical benefit requires direct human evidence rather than extrapolation from protective laboratory signals.
Scientific sources
Zheng Z, Chen M, Feng S, Zhao H, Qu T, Zhao X, Ruan Q, Li L, Guo J. VDR and deubiquitination control neuronal oxidative stress and microglial inflammation in Parkinson’s disease. Cell Death Discovery. 2024;10:150. DOI: 10.1038/s41420-024-01912-9. PMID: 38514643. The complete principal paper, seven figures, supplementary figures S1: S8 and supplementary tables S1: S3 were examined.
Related reading
Vitamin D, Microglia and Oxidative Neuroprotection: Full Study
Examine experimental vitamin D research on microglial inflammation, oxidative injury and neuronal protection, with model-specific mechanisms and human limits.
Read more →Parkinson’s disease-associated alterations in DNA methylation and hydroxymethylation in human brain
Epigenetic mechanisms mediate interactions between aging, genetics, and environmental factors in sporadic Parkinson’s disease (PD).
Original paper ↗Read more →Vitamin D Receptor Activation Influences NADPH Oxidase (NOX2) Activity and Protects against Neurological Deficits and Apoptosis in a Rat Model of Traumatic Brain Injury
In the present study, rats were randomly assigned to the sham, TBI, and calcitriol-treated groups.
Original paper ↗Read more →Vitamin D and omega-3 fatty acids attenuate MSG-induced neurodegeneration by modulating tau pathology, neuroinflammation, and VDR expression in rats
Fifty male Sprague Dawley rats were randomly allocated to a control, an MSG, and three treatment groups that received MSG and either Vit D or N-3 PUFA supplements in combinations or alone for 4 weeks.
Original paper ↗Read more →Microglia‐Derived Vitamin D Binding Protein Mediates Synaptic Damage and Induces Depression by Binding to the Neuronal Receptor Megalin
Vitamin D binding protein (VDBP) is a potential biomarker of major depressive disorder (MDD).
Original paper ↗Read more →Deep clinical, genetic, and serum biomarker profiling indicates glial and neuronal pathology in primary brain calcification
Primary brain calcification (primary familial brain calcification in inherited cases) is an often-genetic condition characterized by symmetrical brain calcifications and neuropsychiatric symptoms.
Original paper ↗Read more →Neuron-Specific Vitamin D Signaling Attenuates Microglia Activation and CNS Autoimmunity
Since IL-34 is critical to the homeostasis of microglia, and was previously shown to be induced in endothelial cells by vitamin D, we investigated IL-34 as the potential anti-inflammatory molecule induced in neurons by vitamin D.
Original paper ↗Read more →Calcitriol confers neuroprotective effects in traumatic brain injury by activating Nrf2 signaling through an autophagy-mediated mechanism
The present study aimed to further explore the potential interaction between oxidative stress and autophagy in the progression of traumatic brain injury (TBI) and therapeutic mechanism of calcitriol, the active form of vitamin D (VitD).
Original paper ↗Read more →Role of Vitamin D in Cognitive Dysfunction: New Molecular Concepts and Discrepancies between Animal and Human Findings
The developmental disabilities induced by vitamin D deficiency (VDD) include neurological disorders (e.g., attention deficit hyperactivity disorder, autism spectrum disorder, schizophrenia) characterized by cognitive dysfunction.
Original paper ↗Read more →Vitamin D Prevents Hypoxia/Reoxygenation-Induced Blood-Brain Barrier Disruption via Vitamin D Receptor-Mediated NF-kB Signaling Pathways
Maintaining blood-brain barrier integrity and minimizing neuronal injury are critical components of any therapeutic intervention following ischemic stroke.
Original paper ↗Read more →Vitamin D receptor is present on the neuronal plasma membrane and is co-localized with amyloid precursor protein, ADAM10 or Nicastrin
The localization of VDR on neuronal membranes and its co-localization with target proteins were investigated with cell surface staining followed by immunofluorescence labelling.
Original paper ↗Read more →Vitamin D, Neural Inflammation and Pain Sensitivity: Full Study
Explore vitamin D studies of sensory nerves, spinal inflammation and pain sensitivity, separating experimental mechanisms from clinical pain-relief claims.
Read more →A molecular systems architecture of asthma
Asthma is a heterogeneous inflammatory disease driven by complex genetic, immunological, environmental, and neuro-immune interactions.
Original paper ↗Read more →ApaI polymorphism of vitamin D receptor affects health-related quality of life in patients with primary sclerosing cholangitis
We investigated the incidence of VDR polymorphisms (rs1544410-BsmI; rs7975232-ApaI; rs731236-TaqI) in a group of patients with primary sclerosing cholangitis (PSC, n = 275) and in healthy controls (n = 376).
Original paper ↗Read more →Biological determinants of blood-based biomarker levels in Alzheimer’s disease: role of nutrition, inflammation, and metabolic factors
While the individual contributions of neuroinflammation, brain insulin resistance, and micronutrient deficiencies to AD pathology are well-established, a significant knowledge gap exists in understanding their intricate, synergistic interactions.
Original paper ↗Read more →Cholecalciferol Supplementation Impacts Behavior and Hippocampal Neuroglial Reorganization in Vitamin D-Deficient Rats
This study aimed to investigate the effects of cholecalciferol supplementation on cognitive function in rats who underwent transient VDD in adulthood.
Original paper ↗Read more →Fok-I, Bsm-I, and Taq-I Variants of Vitamin D Receptor Polymorphism in the Development of Autism Spectrum Disorder: A Literature Review
The role of vitamin D in the development of autism spectrum disorder (ASD) is of intensified interest in medical science in recent years.
Original paper ↗Read more →Multi-omics machine learning classifier and blood transcriptomic signature of Parkinson’s disease
Early diagnosis and biomarker discovery to bolster the therapeutic pipeline for Parkinson’s disease (PD) are urgently needed.
Original paper ↗Read more →Multi-Strain Probiotic Improves Tryptophan Metabolism and Symptoms in Chronic Fatigue Syndrome Patients with Co-Occurring Irritable Bowel Syndrome: An Open-Label Pilot Study
We investigated whether a specific multi-strain probiotic (CDS22-formula) could improve symptoms in women with CFS and co-occurring IBS.
Original paper ↗Read more →Niemann-Pick Type A Disease: Behavior of Neutral Sphingomyelinase and Vitamin D Receptor
Sphingomyelinase (SMase) is responsible for the breakdown of sphingomyelin (SM) with production of ceramide.
Original paper ↗Read more →Vitamin D Genetics Beyond Serum 25(OH)D: VDR rs2228570 (FokI) Polymorphism, Inflammation, and Quality of Life in Orthopedic Patients
This study investigated the rs2228570 (FokI) variant in relation to inflammatory, hematologic, and patient-reported outcomes in orthopedic patients.
Original paper ↗Read more →Original sources
VDR and deubiquitination control neuronal oxidative stress and microglial inflammation in Parkinson’s disease
Published in Cell Death Discovery (2024).
Publication details
Zheng Z, Chen M, Feng S, Zhao H, Qu T, Zhao X, Ruan Q, Li L, Guo J. VDR and deubiquitination control neuronal oxidative stress and microglial inflammation in Parkinson’s disease. Cell Death Discovery. 2024;10:150. DOI: 10.1038/s41420-024-01912-9. PMID: 38514643. The complete principal paper, seven figures, supplementary figures S1: S8 and supplementary tables S1: S3 were examined.